Alexander Drilon MD (@alexdrilon) ranks #23 among US lung cancer KOLs on X in 2026, by engagement from fellow physicians. 12 physicians shared, quoted or replied to their posts this year. CMS Open Payments lists $350 in 2025 general payments.
At a Glance
- 3 colleague posts sharing slides from Alexander Drilon MD's presentations
- Lung Cancer: US #23 · 12 physicians engaged
- Presented at WCLC 2026, ELCC 2026 in 2026
- CMS Open Payments lists $350 in 2025 general payments.
This Month
What Alexander Drilon MD has posted in the last 30 days. Updated November 10, 2026.
No trial posts in the last 30 days.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Lung Cancer | #23 | — | 12 | 14 | Full ranking |
From the Podium, 2025–26
Talks, posters and sessions Alexander Drilon MD presented at SABCS 2025 and 2026 meetings, each confirmed by a public source.
- WCLC 2026 · Plenary (Presidential Symposium, PL03.06)ARROS-1: Zidesamtinib in TKI-naive Patients With Advanced/Metastatic ROS1+ NSCLC: Efficacy and Safety DataARROS-1 trial profile → · Source: @HHorinouchi on X ↗
- ELCC 2026 · Invited lectureEducational session on innovative treatments for fusion+ NSCLC: ROS1Source: @g_mountzios on X ↗
What Colleagues Are Saying About Alexander Drilon MD
2026 posts by fellow physicians that mention @alexdrilon, quoted word for word.
#ELCC26 kick-off with an educational session focusing on innovative treatments for fusion+ in #NSCLC. Insightful presentations by: @bensolomon1 #ALK @alexdrilon #ROS1 @GautschiOliver #RET @ZerAlona #NTRK #TRK Many hyper selective TKIs now available with exceptional and long-lasting systemic and intracranial responses!! @ALKpositiveINT @ALKpositiveINT @alk_fusion @ros1dersuk @RETpositive @RetRenegades @NTRKers @IASLC @myESMO
🆙#WCLC26 #LCSM Plenary Session 🔥ARROS-1: Zidesamtinib in TKI-naive Patients With Advanced/Metastatic ROS1+ NSCLC: Efficacy and Safety Data 🎙️ @alexdrilon 🔢PL03.06 ☑️NCT05253794 🔗 https://t.co/mYsNwaWQUZ @OncoAlert @Larvol @IASLC @ros1cancer https://t.co/KEwTHWEQ5A https://t.co/8rq3OuRfAi
ROS1+ NSCLC update by @alexdrilon at #ELCC26! 💊 Multiple active 1L TKIs…but generation matters 🎯 Newer TKIs → ↑ CNS activity + broader mutation coverage ▪️ Not all ROS1 mutations are equal (e.g. L2086F → type II TKIs) ▪️ Safety profiles differ → key in treatment selection 👎🏻 IO? Still disappointing Emerging players (e.g. zidesamtinib) pushing the field forward From “one target” to precision within ROS1 🎯 @OncoAlert @myESMO @OncoReporte @_SEOM @gecp_org
ARROS-1 update zidesamtinib in ROS1 TKI-naive NSCLC by @alexdrilon at #WCLC26 Take: ORR 94% is possible!!! in TKI-naive patients, with 86% still in response and 90% still progression-free at 12 months. DOR and PFS both not reached. The CNS data answers the open question from July: IC-ORR 100%, IC-CR rate 70%, median IC-DOR not reached, and no CNS progression events among patients without baseline brain mets. Safety consistent with prior reports, low discontinuation/dose-reduction rates. This is a materially stronger picture than the pretreated cohort behind the original approval (44% ORR). Discussion by @Mal_Itchins puts taletrectinib (TRUSTI/II) as the PFS benchmark to beat of 46 m. @ros1cancer #LCSM #lungcancer
The traditional meeting of the three mousquetaires at #ELCC26. @alexdrilon @GautschiOliver building friendship and projects ! https://t.co/nhi7nZkfA4
Dr. @alexdrilon at #WCLC26 presents 1L cohort of ARROS-1 trial of zidesamtinib in pts with ROS1 NSCLC. What a waterfall plot. RR 94% with 15% CR. mPFS not reached, PFS at 6m was 96% and at 12m was 90%. Intracranial RR 100%. In 78 pts who did not have brain metastases at baseline, no CNS events occurred to date. These are fantastic outcomes.
Alexander Drilon MD’s Presentations
Slides from Alexander Drilon MD’s 2026 presentations, as shared by physicians in the audience.
@alexdrilon presents updates from ARROS-1 at @IASLC #WCLC26. The findings in the TKI-naive cohort are impressive! I’ve had the privilege of seeing firsthand how well and quickly this drug works in my clinic. Very exciting! https://t.co/R18ggyBB4k
Dr @alexdrilon presenting ARROS-1, Zidesamtinib for ROS1 NSCLC in 1L. - ORR 94%, PFS NR! #WCLC26 ‼️measurable CNS Mets n=10, IC-ORR 100% - Tox similar to other ROS1 TKIs. ⭐️Another efficacious option joins Taletrectinib! https://t.co/xgsJ0gw1mN
@alexdrilon presenting ARROS-1 trial. You don’t often see ORR this high including CRs. Good response in CNS too. Low rates of tox. I think Zidesamtinib is a game changer for ROS-1 @ros1cancer #LCSM https://t.co/vTxgFAgfSA
Industry Payments
CMS Open Payments · 2025 general payments
$350 across 1 payments